- Home
- ABEO vs MCI Comparison
ABEO vs MCI Comparison
Compare ABEO & MCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABEO | MCI |
|---|---|---|
| Founded | 1974 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.5M | 362.0M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABEO | MCI |
|---|---|---|
| Price | $5.80 | $18.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 43.4K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.46% |
| EPS Growth | ★ 165.16 | N/A |
| EPS | N/A | ★ 1.82 |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $1,024.31 | N/A |
| Revenue Next Year | $145.42 | N/A |
| P/E Ratio | ★ N/A | $9.95 |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $16.57 |
| 52 Week High | $7.54 | $23.00 |
Technical Indicators
Market Signals| Indicator | ABEO | MCI |
|---|---|---|
| Relative Strength Index (RSI) | 58.23 | 62.56 |
| Support Level | $5.20 | $18.00 |
| Resistance Level | $6.07 | $18.08 |
| Average True Range (ATR) | 0.25 | 0.43 |
| MACD | -0.00 | 0.14 |
| Stochastic Oscillator | 75.40 | 67.96 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.